Rajib Dutta

Rajib Dutta

Auto-generated profile, based on publicly available information

Rajib Dutta

Inner West Pain Centre, ISM Care Sydney, NSW, Australia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2017 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
DLDarren M. Lipnicki
Darren M. Lipnicki
JCJohn D. Crawford
John D. Crawford
RDRajib Dutta
Rajib Dutta
Anbupalam ThalamuthuAnbupalam Thalamuthu
Anbupalam Thalamuthu
NKNicole Anita Kochan
Nicole Anita Kochan
C(Cohort Studies of Memory in an International Consortium (COSMIC)
Cohort Studies of Memory in an International Consortium (COSMIC)
The prevalence of dementia varies around the world, potentially contributed to by international differences in rates of age-related cognitive decline. Our primary goal was to investigate how rates of age-related decline in cognitive test performance varied among international cohort studies of cognitive aging. We also determined the extent to which sex, educational attainment, and apolipoprotein E ε4 allele (APOE*4) carrier status were associated with decline. We harmonized longitudinal data for 14 cohorts from 12 countries (Australia, Brazil, France, Greece, Hong Kong, Italy, Japan, Singapore, Spain, South Korea, United Kingdom, United States), for a total of 42,170 individuals aged 54–105 y (42% male), including 3.3% with dementia at baseline. The studies began between 1989 and 2011, with all but three ongoing, and each had 2–16 assessment waves (median = 3) and a follow-up duration of 2–15 y. We analyzed standardized Mini-Mental State Examination (MMSE) and memory, processing speed, language, and executive functioning test scores using linear mixed models, adjusted for sex and education, and meta-analytic techniques. Performance on all cognitive measures declined with age, with the most rapid rate of change pooled across cohorts a moderate -0.26 standard deviations per decade (SD/decade) (95% confidence interval [CI] [-0.35, -0.16], p < 0.001) for processing speed. Rates of decline accelerated slightly with age, with executive functioning showing the largest additional rate of decline with every further decade of age (-0.07 SD/decade, 95% CI [-0.10, -0.03], p = 0.002). There was a considerable degree of heterogeneity in the associations across cohorts, including a slightly faster decline (p = 0.021) on the MMSE for Asians (-0.20 SD/decade, 95% CI [-0.28, -0.12], p < 0.001) than for whites (-0.09 SD/decade, 95% CI [-0.16, -0.02], p = 0.009). Males declined on the MMSE at a slightly slower rate than females (difference = 0.023 SD/decade, 95% CI [0.011, 0.035], p < 0.001), and every additional year of education was associated with a rate of decline slightly slower for the MMSE (0.004 SD/decade less, 95% CI [0.002, 0.006], p = 0.001), but slightly faster for language (-0.007 SD/decade more, 95% CI [-0.011, -0.003], p = 0.001). APOE*4 carriers declined slightly more rapidly than non-carriers on most cognitive measures, with processing speed showing the greatest difference (-0.08 SD/decade, 95% CI [-0.15, -0.01], p = 0.019). The same overall pattern of results was found when analyses were repeated with baseline dementia cases excluded. We used only one test to represent cognitive domains, and though a prototypical one, we nevertheless urge caution in generalizing the results to domains rather than viewing them as test-specific associations. This study lacked cohorts from Africa, India, and mainland China. Cognitive performance declined with age, and more rapidly with increasing age, across samples from diverse ethnocultural groups and geographical regions. Associations varied across cohorts, suggesting that different rates of cognitive decline might contribute to the global variation in dementia prevalence. However, the many similarities and consistent associations with education and APOE genotype indicate a need to explore how international differences in associations with other risk factors such as genetics, cardiovascular health, and lifestyle are involved. Future studies should attempt to use multiple tests for each cognitive domain and feature populations from ethnocultural groups and geographical regions for which we lacked data.

5 March 2025 in Osteoarthritis and Cartilage
Verified
Journal Article
Open access
MAMatheus Almeida
Matheus Almeida
BSBruno T. Saragiotto
Bruno T. Saragiotto
DHDavid Hunter
David Hunter
MDMurillo Dorio
Murillo Dorio
VDVicky Duong
Vicky Duong
LDLeticia Deveza
Leticia Deveza
Osteoarthritis (OA) is a prevalent and disabling joint disorder. Minimally invasive interventions targeting the genicular nerves are widely used for the clinical management of knee OA, but evidence on their efficacy and safety remains uncertain. To assess the efficacy and safety of minimally invasive interventions targeting the genicular nerves in knee OA. We searched MEDLINE, Embase, CENTRAL and clinical trial registries, from inception to August 2024. We included randomised controlled trials evaluating minimally invasive interventions targeting the genicular nerves in patients with knee OA. Comparators included sham/placebo (main comparison), intra-articular injections, and usual care. Data were extracted independently by two reviewers following the PRISMA guidelines. Risk of bias was assessed using the Cochrane RoB-2 tool, and evidence certainty was evaluated according to the GRADE approach. A random-effects meta-analysis was conducted. The primary outcomes were pain intensity, physical function, and serious adverse events. Secondary outcomes included quality of life and patient-reported global perceived effect. Twenty-five trials were included (n= 2049) evaluating radiofrequency ablation (RFA), genicular nerve block (GNB) and cryoneurolysis. The certainty of evidence was consistently low to very low across all comparisons. RFA may provide moderate short-term pain relief (0 - 10 scale) compared to sham at 4 weeks (MD -1.70, 95% CI -3.03 to -0.36) and 12 weeks (MD -1.86, 95% CI -2.82 to -0.89), but there was no benefit at 24 and 48 weeks, and no improvements in function at any time point. The evidence is very uncertain for GNB, with only a single trial suggesting small pain reduction and moderate functional improvements at 4 weeks. For cryoneurolysis, very low certainty evidence suggests minimal short-term effects on pain and function. No differences in serious adverse events were observed between minimally invasive interventions and sham/placebo. The evidence supporting the use of RFA for the management of knee OA is highly uncertain, with modest, short-term benefits that are not sustained. Given the very low certainty of current data, we advise against its routine use until more robust evidence is available. PROSPERO - CRD42023454756.